Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Kentucky: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 36 | 1,007 | 37% |
| 2020 | 22 | 803 | 41% |
| 2021 | 17 | 764 |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Kentucky; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 33 | 1,469−9.4%/yr | −9.4%/yr | 3.10.9× | 1% | 1,500 in 2030+0.4%/yr |
| Lumbar fusion |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Kentucky · Every state · Compare with Texas
| 2024 |
| 605 |
| 57% |
| 2025 est. | ≈ 730 | – |
| 2026 est. | ≈ 730 | – |
| 47% |
| 2022 | 11 | 741 | 52% |
| 2023 | 17 | 744 | 55% |
| 2024 | 10 | 605 | 57% |
| 2025 from claims | – | 727 588–854 | 58% |
| 2026 forecast | – | 725 568–911 | 59% |
| 2027 forecast | – | 726 538–959 | 60% |
| 2028 forecast | – | 726 514–1,002 | 60% |
| 2029 forecast | – | 726 493–1,041 | 61% |
| 2030 forecast | – | 726 475–1,077 | 62% |
In 2025, 59% inpatient hospital, 38% hospital outpatient, 2% surgery center.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 3,684−1%/yr |
| −1%/yr |
| 1.6 |
| 7% |
| 4,300 in 2030+2.6%/yr |
| North Carolina | 26 | 1,686−6.3%/yr | −6.3%/yr | 1.6 | 6% | 1,550 in 2030−1.4%/yr |
| Georgia | 34 | 1,567−5.6%/yr | −5.6%/yr | 1.7 | 7% | 1,710 in 2030+1.4%/yr |
| Virginia | 35 | 1,533−3.6%/yr | −3.6%/yr | 1.4 | 1% | 1,680 in 2030+1.6%/yr |
| Maryland | 34 | 1,470−1.4%/yr | −1.4%/yr | 1.6 | 5% | 1,510 in 2030+0.4%/yr |
| Tennessee | 32 | 1,388−3%/yr | −3%/yr | 1.9 | 6% | 1,430 in 2030+0.5%/yr |
| South Carolina | 31 | 1,151−3.6%/yr | −3.6%/yr | 1.6 | 4% | 1,220 in 2030+0.9%/yr |
| Louisiana | 21 | 996−3.3%/yr | −3.3%/yr | 2.3 | 2% | 1,040 in 2030+0.8%/yr |
| Alabama | 31 | 919−9.6%/yr | −9.6%/yr | 2.0 | 4% | 880 in 2030−0.7%/yr |
| Oklahoma | 28 | 913−6.1%/yr | −6.1%/yr | 1.8 | 0% | 980 in 2030+1.2%/yr |
| Arkansas | 15 | 594−6.2%/yr | −6.2%/yr | 1.5 | 5% | 650 in 2030+1.4%/yr |
| Mississippi | 13 | 506−7.3%/yr | −7.3%/yr | 1.3 | 24% | 500 in 2030−0.3%/yr |
| Delaware | 7 | 283−1.8%/yr | −1.8%/yr | 1.6 | 15% | 360 in 2030+4%/yr |
| West Virginia | 2 | 183−11%/yr | −11%/yr | 0.8 | 0% | 160 in 2030−2.2%/yr |
| District of Columbia | 2 | 158−2.2%/yr | −2.2%/yr | 2.5 | 10% | 160 in 2030−0.2%/yr |
| 33 |
| 1,251−4%/yr |
| −4%/yr |
| 2.60.8× |
| 1% |
| 1,500 in 2030+3.1%/yr |
| Kyphoplasty & vertebroplasty | 5 | 575−12%/yr | −12%/yr | 1.20.7× | 21% | 690 in 2030+3%/yr |
| SI joint fusion | 2 | 100−6.4%/yr | −6.4%/yr | 0.20.6× | 0% | 170 in 2030+8.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Medtronic leads with 27% of company spending on these surgeons in 2025, −44 pts on 2024.
In 2025, 14 companies reported engagement with Kentucky’s surgeons worth $93K in consulting, speaking, meals and travel tied to these products, about $9,329 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.